Napredna pretraga

Pregled bibliografske jedinice broj: 932329

Nonalcoholic fatty liver disease and liver transplantation – Where do we stand?


(Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua 35100, Italy) Mikolašević, Ivana; Filipec-Kanižaj, Tajana; Mijić, Maja; Jakopčić, Ivan; Milić, Sandra; Hrstić, Irena; Štimac, Davor; Burra, Patrizia
Nonalcoholic fatty liver disease and liver transplantation – Where do we stand? // World journal of gastroenterology, 24 (2018), 14; 1491-1506 (međunarodna recenzija, članak, znanstveni)


Naslov
Nonalcoholic fatty liver disease and liver transplantation – Where do we stand?

Autori
Mikolašević, Ivana ; Filipec-Kanižaj, Tajana ; Mijić, Maja ; Jakopčić, Ivan ; Milić, Sandra ; Hrstić, Irena ; Štimac, Davor ; Burra, Patrizia

Kolaboracija
Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua 35100, Italy

Izvornik
World journal of gastroenterology (1007-9327) 24 (2018), 14; 1491-1506

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Nonalcoholic fatty liver disease ; Nonalcoholic steatohepatitis ; Chronic liver disease ; Liver transplantation ; Outcome

Sažetak
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a challenging and multisystem disease that has a high socioeconomic impact. NAFLD/NASH is a main cause of macrovesicular steatosis and has multiple impacts on liver transplantation (LT), on patients on the waiting list for transplant, on post-transplant setting as well as on organ donors. Current data indicate new trends in the area of chronic liver disease. Due to the increased incidence of metabolic syndrome (MetS) and its components, NASH cirrhosis and hepatocellular carcinoma caused by NASH will soon become a major indication for LT. Furthermore, due to an increasing incidence of MetS and, consequently, NAFLD, there will be more steatotic donor livers and less high quality organs available for LT, in addition to a lack of available liver allografts. Patients who have NASH and are candidates for LT have multiple comorbidities and are unique LT candidates. Finally, we discuss long-term grafts and patient survival after LT, the recurrence of NASH and NASH appearing de novo after transplantation. In addition, we suggest topics and areas that require more research for improving the health care of this increasing patient population.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Klinička bolnica "Merkur",
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Rijeka

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE